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 Abstract 
Bilayer tablet is innovative period for the successful improvement of controlled release formulation along with a 
variety of features to provide a technique of successful drug delivery system. Controlled release dosage forms have been 
comprehensively used to improve therapy with several important drugs. Inclusion of drug in controlled release gastro-
retentive dosage forms which can remain in the gastric region for several hours would considerably extend the gastric 
residence time of drugs and improve bioavailability, reduce drug waste and enhance the solubility of drugs that are less 
soluble in high pH environment. Numerous approaches are presently utilized in the prolongation of Gastric Retention Time, 
including floating drug delivery system, swelling and expanding systems, polymeric bio adhesive systems, high-density 
systems, modified shape systems and other deferred gastric emptying strategy.  
Keywords: Bilayer tablet, Controlled release, Gastro retentive dosage forms, bioavailability. 
1. Introduction  
  Oral ingestion has long been the most convenient 
and commonly employed route of drug delivery due to its 
ease of administration. Conventional dosage form produce 
wide ranging fluctuation in drug concentration in the blood 
stream and tissues with consequent undesirable toxicity and 
poor efficiency. The aim in designing sustained or 
controlled delivery systems is to decrease the frequency of 
the dosing or to increase effectiveness of the drug by 
localization at the site of action, reducing the dose required. 
The main objective of sustained release drug delivery is to 
make sure safety and to improve effectiveness of drugs as 
well as patient compliance. [1] Now a day’s various 
developed & developing countries move towards 
combination therapy for treatment of various diseases & 
disorders requiring long term therapy such as hypertension, 
diabetes and Cardio vascular diseases. Bi-layer tablets are 
suitable for sequential release of two drugs in combination, 
separate two incompatible substances and also for sustained 
release tablet in which one layer is immediate release as 
initial dose and second layer is maintenance dose. Bi-layer 
tablets consist of monolithic partially coated or 
multilayered matrices. In the case of bi-layered tablets drug 
release can be rendered almost unidirectional if the drug 
can be incorporated in the upper non-adhesive layer its 
delivery occurs into the whole oral cavity. The mechanical 
strength of bi-layered tablets has been observed not to be a 
controlling factor in drug release.  Challenges during 
development of bi-layer tablets include the order of layer 
sequence, layer weight ratio, and elastic mismatch of the 
adjacent layers, first layer tamping force and cross 
contamination between layers. If these factors are not well 
controlled in one way then other will affect the bi-layer 
compression pressure and the quality attributes like 
mechanical strength and individual layer weight control. 
Therefore care must be taken to enable design of a vigorous 
product and process. [2] In the last decade, interest in 
developing a combination of two or more active 
pharmaceutical ingredients in a single dosage form has 
increased in the pharmaceutical industry, promoting patient 
convenience and compliance. Bi-layer tablets can be a 
primary option to avoid chemical incompatibilities between 
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APIS by physical separation, and to enable the development 
of different drug release profiles (immediate release with 
extended release). [3]  
1.1 Advantages of the bi-layer tablets  
1) Bi-Layer execution with optional single layer 
conversion kit.  
2) The cost is lower compared to all other oral dosage 
forms.  
3) Greatest chemical and microbial stability over all oral 
dosage forms.  
4) Objection able odor and bitter taste can be masked by 
coating technique.  
1.2 Flexible Concept  
1) They are a unit dosage form and offer the greatest 
capabilities of all oral dosage forms for the greatest dose 
precision and the least content variability. 
2) Suitable for large scale production. [4] 
3) This system provide sustained drug delivery like HBS 
dosage form modify gastric residence time as this 
system remain in stomach for many hours.  
4) It maintains optimum therapeutic window as a result 
drug delivery with controlled released is achieved.  
5) Better patient compliance is achieved due to its ease of 
administration.  
6) It maintains constant blood level.  
7) Site specific drug delivery is achieved for the drugs such 
as furosemide and riboflavin which are formulated as 
floating system.  
8) Due to higher dose precision and lesser content variation 
they are the most compatible oral dosage form. .  
9) Better suited for large scale production.   
10) Swallowing of tablets is easy.  
11) Lesser cost compared to other oral dosage forms. 
12) These are the most lighter and compact.[5] 
1.3 Disadvantages of floating bi-layer tablets  
1) Increased fluid levels are required in the stomach so that 
the system float properly.  
2) Drugs with solubility and stability problem in stomach 
cannot be formulated as floating dosage form.  
3) Irritation producing drugs on gastric mucosa can be 
formulated as floating dosage form. 
4) Capping is the major problem in bilayer tablets.  
5) Separation of layer occurs due to insufficient bonding 
and reduction in yield occurs.  
6) Hardness is other problem.  
7) There are chances of cross contamination between two 
layers.  
8) Due to low density and amorphous nature of some drugs 
compacts do not form because they resist compression.  
9) There is less control over weight of individual layer.   
10) Swallowing problem in case of children and 
unconscious patients. 
11) Bioavailability problem occurs in case of poor wetting 
and less dissolution properties. 
12) Sometimes encapsulation or coating is required for the 
drugs that are oxygen sensitive, bitter tasting and with 
bad odor. [5,6] 
1.4 Ideal properties for bi-layer tablet dosage form   
1) Drug must be released in reproducible and expected 
manner in bi-layer tablet.  
2) Chemical and physical stability is must.  
3) During product shelf life chemical stability is main 
concern. 
4) They should be free from visual defects. 
5) A bi-layer tablet should have elegant product identity 
while free of defects like chips, cracks, discoloration and 
contamination. 
6) It should have sufficient strength to with stand 
mechanical shock during its production packaging, 
shipping and dispensing.  
7) It should have the chemical and physical stability to 
maintain its physical attributes over time.  
8) The bi-layer tablet must be able to release the medicinal 
agents in a predictable and reproducible manner.  
9) It must have a chemical stability shelf-life, so as not to 
follow alteration of the medicinal agents. [7, 8] 
1.5 Preparation 
  Bi-layer tablets are prepared with one layer of drug 
for immediate release with the second layer designed to 
release drug later, either as a second dose or in an extended 
release form. The bi-layer tablets with two incompatible 
drugs can also be prepared by compressing separate layers 
of each drug so as to minimize the area of contact between 
two layers.   
1.6 Compaction  
  To produce an adequate tablet formulation, certain 
requirements such as sufficient mechanical strength and 
desired drug release profile must be met. At times, this may 
be a difficult task for the for mulator to achieve these 
conditions, especially in the bi-layer tablet formulation 
where double compression technique is involved, because 
of Poor flow and compatibility characteristic of the drug 
which will result in capping and/or lamination. The 
compaction of a material involves both the compressibility 
and consolidation.   
1.7 Compression  
  It is defined as reduction in bulk volume by 
eliminating voids and bringing particles into closer 
contacts.   
1.8 Consolidation  
  It is the property of the material in which there is 
increased mechanical strength due to inter particulate 
interaction (bonding). The compression force on layer1 was 
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found to be a major factor influencing tablets 
delaminating.[4,8]  
 
2. Methodology used for bi-layer floating tablet 
1) Oros ® Push Pull Technology  
2) L-Oros Tm Technology  
3) DUROS Technology  
4) Elan Drug Technologies’ Dual Release Drug Delivery 
System 
5) EN SO TROL Technology 
6) Rotab Bilayer  
7) Geminex Technology.   
1. Oros ® Push Pull Technology 
  Two or three layer system a drug layer and push 
layer. Drug layer contain drug with other agents and due to 
this drug is less soluble. Sometimes suspending agent and 
osmotic agent are also added. The tablet core is surrounded 
by semi permeable membrane.   
2. L-Oros Tm Technology  
  Alza developed L-OROS system due to solubility 
problem. The system contain a drug in dissolved state in a 
lipid soft gel product which is produced first and then 
barrier membrane, after which osmotic membrane and semi 
permeable membrane coat is applied and is then drilled out 
through external orifice.   
3. DUROS Technology  
  This technology is also known as miniature drug 
dispensing system which works like a miniature syringe and 
release small quantity of drug consistently over a period of 
time .There is an outer cylindrical titanium alloy reservoir 
which has high impact strength due to which drug 
molecules inside it are protected from enzymes.   
4. Elan Drug Technologies’ Dual Release Drug Delivery 
System  
  The DUREDASTM Technology provides 
combination release of drugs together and different release 
pattern of single drug i.e. it provides sustained release as 
well as immediate release. This technology provides 
various advantages i.e. two drug components provide 
tailored release and it’s another benefit is that it consist of 
bilayer tablet technology in which it contain modified as 
well as immediate release pattern in one tablet. In these 
different controlled release formulations are combined 
together.   
5. EN SO TROL Technology  
  An integrated approach is used by Shire laboratory 
for drug delivery system which focus on identification and 
incorporation of enhancer which is identified to form 
optimized dosage form in controlled release system. By this 
enhancement in solubility is achieved.   
 
 
6. RoTab Bilayer   
a. Software:  
  It is modular designed software to which 
additional functions can be added. PC- system with 15” 
touch- screens is an advanced system which provides fast 
graphical evaluations with accurate results.   
b. Working:  
  Ro Tab bi-layer when using is switched to 
production mode. Dose and compression force is 
automatically regulated by adjusting filling speed and die 
table. Hardness is also regulated when required.  
c. R and D modified technique:  
  R and D modified Ro Tab Bi-layer is featured with 
measuring points on which there are graphical visualization 
and evaluation are possible. There is an additional alarm 
function on which punch tightness is controlled. Anytime 
up gradation is possible which are R and D Plus.  
d. R and D Plus:  
  R and D Plus provides improved standards in 
tabletting technology with all important functions such as 
punch tightness control, display of force displacement and 
tablet scraper force.   
7. Geminex Technology  
  In this drug delivery system at different time more 
than one drug can be delivered. This technology basically 
increases the therapeutic efficacy of the drug by decreasing 
its side effects. It is useful both to industry as well as 
patient as in single tablet it provides delivery of drug at 
different rates. [4, 5, 9, 10]   
 
3. Preformulation of drug 
Particle size distribution:  
  The particle size distribution was measured using 
sieving method.  
Photo microscope study:  
  Photo-microscope image of TGG and GG was 
taken (×450 magnifications) by photomicroscope  
Angle of repose:  
  It is defined as the maximum angle possible 
between the surface of pile of the powder and the horizontal 
plane. Fixed funnel method was used. A funnel was fixed 
with its tip at a given height (h), above a flat horizontal 
surface on which a graph paper was placed. Powder was 
carefully poured through a funnel till the apex of the conical 
pile just touches the tip of funnel. The angle of repose was 
then calculated using the formula,   
Tan θ = h/r 
Where h and r are the height and radius of the powder cone. 
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Moisture sorption capacity: 
  All disintegrates have capacity to absorb moisture 
from atmosphere which affects moisture sensitive drugs. 
Moisture sorption capacity was performed by taking 1 g of 
disintegrate uniformly distributed in petri-dish and kept in 
stability chamber at 37±1oC and 100% relative humidity 
for 2 days and investigated for the amount of moisture 
uptake by difference between weights.   
Density  
  The loose bulk density (LBD) and tapped bulk 
density (TBD) were determined and calculated using the 
following formulas, 
LBD
1/4 
weight of the powder = volume of the packing  
TBD
1/4
 weight of the powder = tapped volume of the 
packing  
Compressibility index 
  The compressibility index of the disintegrate was 
determined by Carr’s compressibility index.   
C = 100 x (1-ÞB/ÞT) [I.P., 1996; U.S. P., 2000:1944].   
  The propensity of the powder to be compressed is 
measured by compressibility index and it also helps in 
measurement of settling property and inter particulate 
interaction.   
Compressibility index (%) = ρt – ρo* 100 / ρt 
Where ρt = Tapped density g/ml, ρo = Bulk density g/ml.  
Bulk Density (Db)   
  It is the ratio of powder to bulk volume. The bulk 
density depends on particle size distribution, shape and 
cohesiveness of particles. Accurately weighed quantity of 
powder was carefully poured into graduated measuring 
cylinder through large funnel and volume was measured 
which is called initial bulk volume. Bulk density is 
expressed in gm/cc and is given by,                                                                   
Db = M / Vo 
Tapped Density (Dt) 
  Ten grams of powder was introduced into a clean, 
dry 100ml measuring cylinder. The cylinder was then 
tapped 100 times from a constant height and tapped volume 
was read. It is expressed in gm/cc and is given by,                           
Dt = M / Vt 
Tapped density= Weight of powder taken/ Tapped Volume   
Hausner’s ratio  
It is calculated by the formula,  
Hausner ratio= Tapped density/ Bulk density 
Hausner ratio= Vo/Vf 
Where, Vo= Unsettled apparent volume, Vf= Final tapped 
volume. 
                                             OR   
H = ρT/ρB 
Where ρB is the freely settled bulk density of the powder, 
and ρT is the tapped density of the Powder. [3, 11, 12, 13] 
 
4. Characterization of tablet 
General Appearance:  
  The general appearance of a tablet, its visual 
identity and overall “elegance” is essential for consumer 
acceptance. Includes in are tablet’s size, shape, color, 
presence or absence of an odor, taste, surface texture, 
physical flaws and consistency and legibility of any 
identifying marking.   
Size and Shape:  
  The size and shape of the tablet can be 
dimensionally described, monitored and controlled. 
Tablet Thickness 
  In this three tablets are randomly taken and then 
their thickness and diameter are measured by Vernier 
caliper or by using calibrated screw gauze.    
Hardness  
  Expressed in kg/cm2 and it is checked using 
Monsanto hardness tester by randomly picking three tablets. 
Hardness helps in knowing ability of the tablet to withstand 
mechanical shock during handling of tablets.   
Friability  
  Ten tablets are selected and weighed and then 
placed in friabilator apparatus which rotate at 25 rpm speed 
for 4 minutes. After 4 minutes tablets are weighed again. 
%F= [1-(Wt/W)]*100 
Where W– Initial weight of tablet, Wt - Weight of tablet 
after revolution.  
  If % Friability of tablets is less than 1% is 
considered acceptable.   
Weight variation  
  Weight variation was carried out for both 
immediate release and sustained release layers. 20 tablets 
were weighed and the average weight was calculated. Then 
the tablets were weighed individually. The percentage 
weight deviation of each tablet from average weight was 
calculated using the following formula    
% deviation = Average weight-individual weight/average 
weight ×100 
Assay/drug content 
  Ten tablets were selected randomly, weighed and 
triturated; a quantity of triturate equal to 100mg of 
Verapamil HCl was transferred to 100ml volumetric flask 
and was dissolved in 0.1N HCl. It was sonicated for 30 min 
and filtered through 0.45µm membrane filter. The 
absorbance after suitable dilutions was measured in a UV 
Visible Spectrophotometer at 278 nm using 0.1N HCl as 
blank.   
In vitro Buoyancy Studies  
  The in vitro buoyancy was determined by floating 
lag time. The tablets were placed in a beaker containing 
100mL 0.1N HCl and the time required for the tablet to rise 
to the surface and float was determined as floating lag time. 
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 In vitro Dissolution Studies  
  Release rate of all the designed formulations were 
studied up to 12 hours using USP type II dissolution 
apparatus (Rotating Paddle method) at 75 rpm. A distance 
of 2.5 cm± 0.2 cm was maintained between the paddle and 
bottom of dissolution vessel. The dissolution medium (900 
ml) consisted of 0.1N hydrochloric acid (1.2 pH), 
maintained at 37oC ± 0.5 
o
C. Sample of 5 ml was 
withdrawn at specific time intervals throughout the 
dissolution study of 12 hours for analysis and replaced with 
fresh dissolution medium. After appropriate dilution the 
samples were analyzed for Verapamil HCl using UV-
Visible spectrophotometer at 278nm. The release studies 
were conducted in triplicate.   
Stability Studies  
  The selected formulations were subjected for 
stability studies based on their drug content and in-vitro 
drug release characteristics. The formulations were stored 
in tightly closed amber coloured glass container in stability 
chamber. The formulations were stored at different storage 
conditions like 50C/Ambient, 250 C/ 60 % RH and 400C/ 
75 % RH for 60 days. The formulations were subjected to 
different tests namely hardness, drug content and in-vitro 
drug release study after 60 days and reported.   
Tablet Density   
  t is an important parameter in case of floating 
tablets. If density is less than (1.004) gastric fluid, than only 
the tablets will float. It is calculated using formula: V=πr2h, 
d = m/v, r = Radius of tablet, h = crown thickness (g/cc), m 
= Mass of tablet.   
Disintegration Time  
  In this one tablet is placed in disintegration 
apparatus containing buffer 0.1N HCl or PBS pH 6.8 and 
test is carried out at 37oC. The time taken by tablet to 
Disintegrate is noted as disintegration time.     
Floating Lag Time   
  It is the time interval taken by the tablets to start 
floating. It should be less than one minute. It is measured 
by dissolution test apparatus containing 0.1 N HCl (900ml).   
Floating Time   
  It is the total time taken by which the tablets 
remain floating in the media.   
Drug Content Uniformity  
  Ten tablets are taken and powdered equivalent 
weight of drug dose is taken and is transferred to volumetric 
flask and then buffer is added and absorbance is determined 
using U.V spectrophotometer.   
Swelling Study  
  Initially tablet is weighed (W1) and placed in a 
glass beaker, containing 200 mL of 0.1 N HCl, maintained 
in a water bath at 37 ± 0.5 _C. At different time intervals, 
the tablet is removed and the excess of liquid is carefully 
removed by a filter paper. The swollen tablet is reweighed 
(W2). The swelling index (SI) is calculated using the 
formula   
SI= Wt -W0/W0*100 
Wt= (Weight of swollen tablet), W0= (Initial weight of 
tablet).   
In-vivo evaluation  
Radiology  
  X-ray is widely used for examination of internal 
body systems. Barium Sulphate is widely used Radio 
Opaque Marker. So, BaSO4 is incorporated inside dosage 
form and X-ray images are taken at various intervals to 
view gastric retention.   
Scintigraphy 
  Similar to X-ray, emitting materials are 
incorporated into dosage form and then images are taken by 
scintigraphy. Widely used emitting material is 99Tc.   
Gastroscopy  
  Gastroscopy is peroral endoscopy used with fiber 
optics or video systems. Gastroscopy is used o inspect 
visually the effect of prolongation in stomach. It can also 
give the detailed evaluation of GRDDS.   
Magnetic Marker Monitoring   
  In this technique, dosage form is magnetically 
marked with incorporating iron powder inside, and images 
can be taken by very sensitive bio-magnetic measurement 
equipment. Advantage of this method is that it is radiation 
less and so not hazardous.   
Ultrasonography 
  Used sometimes, not used generally because it is 
not traceable at intestine.   
13C Octanoic Acid Breath Test  
  13C Octanoic acid is incorporated into GRDDS. In 
stomach due to chemical reaction, octanoic acid liberates 
CO2 gas which comes out in breath. The important Carbon 
atom which will come in CO2 is replaced with 13C isotope. 
So time up to which 13CO2 gas is observed in breath can 
be considered as gastric retention time of dosage form. As 
the dosage form moves to intestine, there is no reaction and 
no CO2 release. So this method is cheaper than other. [10, 
13-15]
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5. Recent development in the field of bilayer tablet 
Table 1: Various Advancements in the Field of Bilayer Tablets 
Drug Dosage Form Rationale Ref. No. 
Diclofenac,Cyclobenzaprine Bi-layer tablets Synergistic effect in pain [16] 
Granisetron HC1 Bi-layer buccal tablets To overcome bioavailability problem, reducing 
side effect 
[17] 
MetforminHC1. Glimipiride Bi-layer tablets Synergistic effect in diabetes [18] 
Indomethacin Bi-layer floating tablet  Biphasic drug release [19] 
MetforminHC1 Atorvastatin 
Calcium 
Bi-layer tablet To develop poly therapy for the treatment of 
NIDDS& hyperlipidemia 
[20] 
Cefixime Trihydrate 
Dicloxacilline Sodium 
Bi-layer tablet Synergistic effect in bacterial infections [21] 
Piracetam, Vinpocetin Bi-layer tablet Synergistic effect in Alzheimer disease [22] 
MetforminHCl, Pioglitazone Bilayer tablet Synergistic effecting diabetes mellitus [23] 
Atenolol Bilayer buccal tablet  Toovercome bioavailability problem, reducing 
side effects and frequency of administration 
[24] 
Cefuroxime Axetil Potassium 
Clavulanate 
Bilayer tablets Synergistic effect against microbial infections and 
to minimize dose dependent side effects 
[25] 
Amlodipine Besilate 
Metoprolol Succinate 
Bilayar tablet  Synergistic effect in hypertension  [26] 
Diclofenac Sodium, 
Paracetamol 
Bilayer tablet  Synergistic effect in pain  [27] 
Ibuprofen, Methocarba-mol Bilayer tablet  Synergistic effect of drugs in back pain [28] 
Atorvastatin, Calcium Bilayer buccal tablet  To overcome bioavailability problem, reducing 
side effects and frequency of administration 
[29] 
Paracetamol, Diclofenac Bilayer tablet  Synergistic effect of drugs in pain [30] 
Losartan Bilayer tablet  Biphasic release profile [31] 
Metformin HCl, Pioglitazone Bilayer tablet   Synergistic effect in diabetes mellitus [32] 
Guaifenesin Bilayer tablet  Biphasic release profile [33] 
Tramadol, Acetaminophen Bilayer tablet  Synergistic effect of drugs in pain [34] 
Atenolol, Lovastatin bilayer floating tablet  Synergistic effect in hypertension and biphasic 
release profile 
[35] 
Montelukast, Levocetrizine Bilayer tablet To improve the stability of drugs in combination [36] 
Salbutamol, Theophylline Bilayer tablet Synergistic effect of drugs in asthma [37] 
Glipizide, Metformin HCl Bilayer tablet  To avoid interaction b/w incompatible drugs [38,39] 
Telmisartan 
Hydrochlorothiazide 
Bilayer tablet To minimize contact b/w hydrochlorothiazide& 
basic component of telmisartan 
[40] 
Amlodipine, Atenolol Bilayer tablet  To improve the stability of drugs in combination [41] 
Ascorbic acid, Cyano-
cobalamin 
Double layer 
suppositories 
 To avoid interaction b/w incompatible vitamins [42] 
Rifampicin, Isoniazid  Capsule & tablet in 
capsule 
To avoid interaction b/w incompatible  drugs [43] 
Misorostol, Diclofenac Bilayer tablet To minimize contact b/w drugs [44] 
Propranolol HCl Bilayer tablet  Bimodal drug release [45] 
Artesunate, Amlodipine Tablet in tablet  To minimize contact b/w drugs [46] 
Telmisartan, Simvastatin Bilayer tablet  To minimize contact b/n Simvastatin & 
telmisartan 
[47] 
Cefuroxime Axetil Bilayer floating tablet Bimodal drug release [48] 
Metformin, Glipizide Bilayer tablet Synergistic effect of drugs in diabetes [49] 
Ranitidine Aspirin Single layer coated 
tablets 
To minimize the contact of  two incompatible 
drugs 
[50] 
Aspirin Ranitidine Single layer tablets To minimize the contact of  two incompatible 
drugs 
[51] 
Statin Aspirin Bilayer tablet To minimize interaction b/w two drugs and side 
effects due to aspirin 
[52] 
Furosemide Bilayer floating tablets To enhance bioavailability [53] 
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Recent advances  
Strübing et al investigated the mechanism of 
floating and drug release behaviour of poly (vinyl acetate)- 
based floating tablets with membrane controlled drug 
delivery. Tablets containing propranolol HCl with 
Kollidon® SR as an excipient for direct compression and 
different Kollicoat® SR 30 D/Kollicoat® IR coats, varying 
from 10 to 20 mg polymer/cm2, were investigated with 
regard to drug release in 0.1 mol/l HCl. Furthermore, the 
onset of floating, the floating duration and the floating 
strength of the device were determined. In addition, bench 
top MRI studies of selected samples were performed. 
Coated tablets with a 10 mg polymer/cm2 SR/IR, and an 
8.5: 1.5 coating exhibited the shortest lag-times prior to 
drug release and the onset of floating, and also the fastest 
increase in and the highest maximum values of the floating 
strength. Jang et al prepared a gastro-retentive drug delivery 
system of DA-6034, a new synthetic Flavonoids derivative, 
for the treatment of gastritis using an effervescent floating 
matrix system (EFMS). The therapeutic limitations of DA-
6034 caused by its low solubility in acidic conditions were 
overcome by using the EFMS, which was designed to allow 
the tablets to float in gastric fluid and release the drug 
continuously. The release of DA-6034 from the tablets in 
acidic media was significantly improved by using EFMS, 
and this was attributed to the effect of the solubilizers and 
the alkalizing agent such as, sodium bicarbonate, used as 
gas generating agent. DA-6034 EFMS tablets showed 
enhanced gastro-protective effects in gastric ulcer induced 
beagle dogs, indicating the therapeutic potential of EFMS 
tablets for the treatment of gastritis. [54-56] 
Future potential for bilayer floating tablets 
Future prospects with respect to herbal drugs 
Herbal drug delivery is the emerging field in the pharmacy. 
The use of FBDDS for herbal medicament is the novel 
approach for the better delivery. The drug release profile 
has been a major focusing area for the pharmaceutical 
research scientists for the past two decades. The scientists 
are finding it a great opportunity to work on GI transit 
profiles. This has given rise to new products with 
substantial benefits to the patients. Now with the advent of 
FBDDS the products have been designed which could 
release drug for up to 12 or 24 hrs. Using bilayer floating 
approach combination of two herbal drugs can be also 
given for more therapeutic effect. Bilayer floating also 
provides the IR and SR concept for herbal drug as well. 
Bilayer floating tablets can be beneficial in hypertension 
and diabetes as immediate response can be achieved by 
using loading dose as one layer along with sustained release 
layer which will maintain the concentration of the drug in 
plasma for prolonged period of time. [57, 58] 
 
6. Conclusion  
Bilayer tablet is superior technology to prevail 
over the deficiency of single layered tablet. Bilayer tablets 
provide one of the significant intend approaches where 
incompatible drugs, with different suggestion and same 
drug with different release rate can be integrated in a single 
unit. Bilayer tablet is suitable for chronological release of 
two drugs in combination, separate two incompatible 
substances and also for sustained release tablet in which 
one layer is immediate release as initial dose and second 
layer is maintenance dose. Many different types of presses 
are being used to produce bilayer tablets, ranging from 
simple single-sided press to highly sophisticated machines. 
The preparation of tablets in the form of bilayers is used to 
provide systems for the administration of drugs, which are 
incompatible and to provide controlled release tablet 
preparations by providing surrounding or multiple swelling 
layers. 
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